Efficacy and Safety of Angong Niuhuang Wan for Stroke

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

Also called NCT04236427

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 2/3
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04236427
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Hong Kong SAR China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04236427. Randomized; quadruple masking; primary purpose prevention. Start 2019-10-15 (actual); primary completion 2022-12-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Angong Niuhuang Wan for Stroke
Condition
Stroke (CVA) or TIA (transient ischemic attack)
Intervention (Drug)
Angong Niuhuang Wan
Intervention (Drug)
Angong Niuhuang Wan Placebo
Lead sponsor
Chinese University of Hong Kong (class: other)

Record details

Record id
cardio:ct-nct04236427
Content hash
67fd884b0734d286fcf8e64ff510ffed430255417d171ceedc8d7c33b5051257